insights_auto
6160 の上昇理由: 4.36%?
さらに詳しくchevron_right
6160:HKG
BeOne Medicines AG
HK$225.00
arrow_upward
+4.36%(+9.40) 1 日
10月16日, 16:08:14 GMT+8 · HKD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_auto6160 の上位の分析情報を生成しています...
始値
HK$224.80
高値
HK$230.20
安値
HK$221.80
時価総額
3557.63億
平均出来高
292.98万
取引量
441.39万
株価収益率
65.67
52 週高値
HK$235.60
52 週安値
HK$153.00
EPS
HK$3.43
発行済株式数
14.26億
従業員数
1万
始値
HK$224.80
高値
HK$230.20
安値
HK$221.80
時価総額
3557.63億
平均出来高
292.98万
取引量
441.39万
株価収益率
65.67
52 週高値
HK$235.60
52 週安値
HK$153.00
EPS
HK$3.43
発行済株式数
14.26億
従業員数
1万
ニュース記事
情報源: ウェブソース、ニュース パートナー
プロフィール
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
BeOne Medicines AG について